REV-600

N/A

Report date: 2026/03/19 16:57:29

Base Information

Drug NameREV-600

Drug Alias NameAnti-CD3/Undisclosed Target Bispecific T-cell Engager Antibody (Revitope Oncology)REV-600

ClassificationSmall molecules > Prodrug > Directed prodrug therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRevitope Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesRevitope Oncology Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A